Table 1.

Correlation between SPP1⁺ TAMs and clinical features of patients enrolled in the ZSH cohort.

Characteristics	Patients		SPP1+ TAMs
	No.	%	Low	High	P
All patients	264	100	149	115
Sex					0.741
Female	104	39.4	60	44
Male	160	60.6	89	71
Age					0.700
≤60	125	47.3	69	56
>60	139	52.7	80	59
Liver cirrhosis					0.183
No	191	72.3	103	88
Yes	73	27.7	46	27
Microvascular invasion					0.081
No	189	71.6	113	76
Yes	75	28.4	36	39
LN metastasis					0.048
No	212	80.3	126	86
Yes	52	19.7	23	29
Tumor number					0.001
Single	201	76.1	125	76
Multiple	63	23.9	24	39
Tumor size					0.004
≤5 cm	118	44.7	78	40
>5 cm	146	55.3	71	75
Tumor differentiation					0.699
I–II	93	35.2	51	42
II–III	171	64.8	98	73
CA199					0.009
≤37 U/ml	118	44.7	77	41
>37 U/ml	146	55.3	72	74
CEA					0.002
≤5 ng/ml	193	73.1	120	73
>5 ng/ml	71	26.9	29	42
GGT					0.005
≤60 U/l	143	54.2	92	51
>60 U/l	121	45.8	57	64
AJCC 8th					0.089
I–II	208	78.8	123	85
IIIa–IIIb	56	21.2	26	30

LN, lymph node; CEA, carcinoembryonic antigen; GGT, γ-glutamyl transpeptidase; AJCC, American Joint Committee on Cancer.

Bold indicated statistical significance.